Armel Herve Nwabo Kamdje

Prof. Dr. Armel Herve Nwabo Kamdje

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2012 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
SDSefirin Nange DJIOGUE
Sefirin Nange DJIOGUE
AKArmel Herve Nwabo Kamdje
Armel Herve Nwabo Kamdje
LVLorella Vecchio
Lorella Vecchio
MKMaulilio John Kipanyula
Maulilio John Kipanyula
MFMohammed Farahna
Mohammed Farahna
PEPaul Faustin Seke Etet
Paul Faustin Seke Etet
Insulin, IGF1, and IGF2 are the most studied insulin-like peptides (ILPs). These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as associated immune deregulations. A growing body of evidence suggests that insulin and IGF1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus play a pivotal role in cell fate determination. Despite the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation, and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of ILPs as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening and novel approaches to controlling tumor development.

14 July 2011 in Blood
Verified
Journal Article
Open access
PDF file
AKArmel Herve Nwabo Kamdje
Armel Herve Nwabo Kamdje
FMFederico Mosna
Federico Mosna
Francesco BifariFrancesco Bifari
Francesco Bifari
VLVeronica Lisi
Veronica Lisi
GBGiulio Bassi
Giulio Bassi
MKMauro Krampera
Mauro Krampera
Although many literature data are available on the role of Notch signaling in T-cell acute lymphoblastic leukemia (ALL) biology, the importance of this molecular pathway in the development of B-lineage ALL (B-ALL) cells in the BM microenvironment is unknown so far. In this study, we used anti-Notch molecules neutralizing Abs and γ-secretase inhibitor (GSI) XII to investigate the role of the Notch signaling pathway in the promotion of human B-ALL cell survival in presence of stromal cell support. The treatment with combinations of anti-Notch molecule neutralizing Abs resulted in the decrease of B-ALL cell survival, either cultured alone or cocultured in presence of stromal cells from normal donors and B-ALL patients. Interestingly, the inhibition of Notch-3 and -4 or Jagged-1/-2 and DLL-1 resulted in a dramatic increase of apoptotic B-ALL cells by 3 days, similar to what is obtained by blocking all Notch signaling with the GSI XII. Our data suggest that the stromal cell–mediated antiapoptotic effect on B- ALL cells is mediated by Notch-3 and -4 or Jagged-1/-2 and DLL-1 in a synergistic manner.

1 January 2017 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
AKArmel Herve Nwabo Kamdje
Armel Herve Nwabo Kamdje
PKPaul TAKAM KAMGA
Paul TAKAM KAMGA
STSimo Richard Tagne
Simo Richard Tagne
LVLorella Vecchio
Lorella Vecchio
ESEtet Paul Faustin Seke
Etet Paul Faustin Seke
MKMauro Krampera
Mauro Krampera
Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog

1 February 2013 in Cellular Signalling
Verified
Journal Article
Closed access
MKMaulilio John Kipanyula
Maulilio John Kipanyula
PEPaul Faustin Seke Etet
Paul Faustin Seke Etet
LVLorella Vecchio
Lorella Vecchio
MFMohammed Farahna
Mohammed Farahna
ENElias Nchiwan Nukenine
Elias Nchiwan Nukenine
AKArmel Herve Nwabo Kamdje
Armel Herve Nwabo Kamdje

7 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
PKPaul TAKAM KAMGA
Paul TAKAM KAMGA
GBGiulio Bassi
Giulio Bassi
ACAdriana Cassaro
Adriana Cassaro
MMMartina Midolo
Martina Midolo
MTMariano Di Trapani
Mariano Di Trapani
MKMauro Krampera
Mauro Krampera
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia

25 May 2012 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AKArmel Herve Nwabo Kamdje
Armel Herve Nwabo Kamdje
GBG Bassi
G Bassi
LPL Pacelli
L Pacelli
GMG Malpeli
G Malpeli
EAE Amati
E Amati
MKMauro Krampera
Mauro Krampera
Stromal cells are essential components of the bone marrow (BM) microenvironment that regulate and support the survival of different tumors, including chronic lymphocytic leukemia (CLL). In this study, we investigated the role of Notch signaling in the promotion of survival and chemoresistance of human CLL cells in coculture with human BM-mesenchymal stromal cells (hBM-MSCs) of both autologous and allogeneic origin. The presence of BM-MSCs rescued CLL cells from apoptosis both spontaneously and following induction with various drugs, including Fludarabine, Cyclophosphamide, Bendamustine, Prednisone and Hydrocortisone. The treatment with a combination of anti-Notch-1, Notch-2 and Notch-4 antibodies or γ-secretase inhibitor XII (GSI XII) reverted this protective effect by day 3, even in presence of the above-mentioned drugs. Overall, our findings show that stromal cell-mediated Notch-1, Notch-2 and Notch-4 signaling has a role in CLL survival and resistance to chemotherapy. Therefore, its blocking could be an additional tool to overcome drug resistance and improve the therapeutic strategies for CLL.